Home » Soligenix Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn’s Disease
Soligenix Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn’s Disease
Soligenix, a development stage biopharmaceutical company, announced that the FDA has completed its review and cleared the IND application for SGX203 (oral beclomethasone 17,21-dipropionate) for the induction treatment of pediatric Crohn’s disease.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
07May
-
14May
-
30May